TPST — Tempest Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $34.53m
- $14.06m
- 24
- 16
- 33
- 14
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 45.4 | 36 | 27 | 34.6 | 29.2 |
Operating Profit | -45.4 | -36 | -27 | -34.6 | -29.2 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -44.6 | -36.4 | -28.3 | -35.7 | -29.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -44.6 | -36.4 | -28.3 | -35.7 | -29.5 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -44.6 | -36.4 | -28.3 | -35.7 | -29.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -44.6 | -36.4 | -28.3 | -35.7 | -29.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -48.8 | -28.9 | -7.47 | -3.09 | -1.91 |